Skip To Main Content
Mubarak Patel on Muck Rack

Mubarak Patel

As seen in: BMJ Oncology, SAGE Publishing
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mubarak

Contact Mubarak, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Commentary: Exploring predictors of perceived stress: a cross-sectional study among nursing students during their clinical practice

|
By Mubarak Patel
| SAGE Publishing
We value your privacy We and our store and/or access information on a device, such as cookies and process personal data, such as unique identifiers and standard information sent by a device for personalised ads and content, ad and content measurement, and audience insights, as well as to develop and improve products. With your permission we and our partners may use precise geolocation data and identification through device scanning.
Open in Who Shared View Duplicates (697) Issue with article?

Risk factors for newly-developed cardiovascular disease and quality of life during the COVID - 19 pandemic: an analysis of the English longitudinal study of ageing - PubMed

|
By Olalekan A. Uthman, Mubarak Patel
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (612) Issue with article?

Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data

|
By Helena Earl, Louise Hiller, Janet Dunn, Mubarak Patel
| BMJ Oncology Verified
Four previous trials do not show non-inferiority for reduced duration trastuzumab, although the Persephone trial confirmed non-inferiority for 6 months trastuzumab compared with 12 months. Nine meta-analyses of reduced duration trastuzumab are available, but this one is the first to use individual patient data. This meta-analysis demonstrates that 6 months of adjuvant trastuzumab is as good as 12 months.
Open in Who Shared Issue with article?
See all 3 articles